CClinicalTrials.gg
Sign In
CompletedNCT02996734GCTLIMBSUpdated Dec 22, 2016

Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment

An observational study in Giant Cell Tumor of Bone, sponsored by Istituto Ortopedico Rizzoli. Completed. Per ClinicalTrials.gov, last updated 2016-12-22.

Sponsored by Istituto Ortopedico Rizzoli · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
412
Sex
All
01

Study summary

The purpose of this project is to present the outcomes of patients with giant cell tumor of bone (GCTB) who were treated with surgery and/or medical treatment in a single institution.

Read the detailed description

The investigators retrospectively review patients treated for GCTB of the extremities between 1990 and 2013 in a single institution. We evaluate the recurrence free survival rate after surgical and medical treatment of patients with GCTB of the extremities to determine the influence of the surgical approach, denosumab therapy, local tumor presentation, and demographic factors on the risk of recurrence.

02

Conditions studied

  • Giant Cell Tumor of Bone

Keywords

  • bone tumors
  • giant cell tumor
  • treatment
03

In context

Giant Cell Tumors

31 studies on the registry are indexed under Giant Cell Tumors; 4 are open to participants now.

Browse Giant Cell Tumors studies →

Lead sponsor

Istituto Ortopedico Rizzoli is the lead sponsor of 298 studies on the registry; 102 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with giant cell tumor of bone treated in a single institution

Inclusion criteria

  • giant cell tumors of the extremities

Exclusion criteria

Exclusion Criteria:

  • giant cell tumors of the spine and pelvis
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
412 participants (actual)
Patient registry
No

Interventions

  • Procedurecurettage and resection

    the investigators analyzed patients with giant cell tumor of bone who underwent curettage or resection with or without denosumab administration

    Also known as: denosumab

06

What researchers measure

Primary outcomes

  1. local recurrence rate after surgical and medical treatment

    Time frame: within the first 36 months after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Tsukamoto S, Mavrogenis AF, Leone G, Righi A, Akahane M, Tanzi P, Kido A, Honoki K, Tanaka Y, Donati DM, Errani C. Denosumab does not decrease the risk of lung metastases from bone giant cell tumour. Int Orthop. 2019 Feb;43(2):483-489. doi: 10.1007/s00264-018-4085-6. Epub 2018 Aug 11. Erratum In: Int Orthop. 2019 Feb;43(2):491. doi: 10.1007/s00264-018-4166-6. PubMed 30099641 ↗

Individual participant data

Plan to share: Yes — publish a manuscript in international medical journal

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02996734
Lead sponsor
Istituto Ortopedico Rizzoli
Responsible party
Costantino Errani (MD; PhD., Istituto Ortopedico Rizzoli) — Principal investigator
First posted
Dec 19, 2016
Start date
Apr 2016
Primary completion
Dec 2016
Completion
Dec 2016
Last update
Dec 22, 2016

Study contacts

Davide Donati, MD
study director · Istituto Ortopedico Rizzoli

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Giant Cell Tumors→

Other studies from this sponsor

Istituto Ortopedico Rizzoli

Start the discussion